Frankfurt - Delayed Quote EUR

Genmab A/S (GE91.F)

25.40 -1.00 (-3.79%)
As of 8:04 AM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GE91.F

Recent News: GE91.F

View More
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media

Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media
The Wall Street Journal 22 days ago
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio

Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio
The Wall Street Journal 22 days ago
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Business Wire 23 days ago
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Business Wire last month
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Business Wire 2 months ago
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Business Wire 3 months ago
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
Business Wire 3 months ago
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Business Wire 4 months ago

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
PR Newswire 4 months ago
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Business Wire 4 months ago
Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Business Wire 5 months ago
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
Business Wire 6 months ago
View More

Related Tickers

EFTRW eFFECTOR Therapeutics, Inc.
0.0385
+54.62%
 
RVX.TO Resverlogix Corp.
0.0550
-8.33%
 
CGON CG Oncology, Inc.
36.20
+0.42%
 
MLTX MoonLake Immunotherapeutics
42.25
-0.42%
 
APGE Apogee Therapeutics, Inc.
45.86
-1.46%
 
AKRO Akero Therapeutics, Inc.
18.93
-6.56%
 
CORT Corcept Therapeutics Incorporated
22.21
-1.20%
 
SGMO Sangamo Therapeutics, Inc.
0.5030
+2.03%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.71
-0.06%
 
RARE Ultragenyx Pharmaceutical Inc.
43.85
-0.97%